Home | About us | Editorial board | Ahead of print | Current issue | Archives | Search | Submit article | Instructions | Subscribe | Advertise | Contact us |  Login 
National Journal of Maxillofacial Surgery
Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 209
Year : 2021  |  Volume : 12  |  Issue : 1  |  Page : 106-108

Management of parotid fistula and Frey's syndrome with Botulinum neurotoxin type A

1 Department of Oral and Maxillofacial Pathology, Hi-Tech Dental College and Hospital, Bhubaneswar, Odisha, India
2 Department of ENT, Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, West Bengal, India

Correspondence Address:
Dr. Ripon Chowdhury
Department of Oral and Maxillofacial Pathology, Hi-Tech Dental College and Hospital, High Tech Hospital Road, Pandara, Rasulgarh, Bhubaneswar - 751 025, Odisha
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/njms.NJMS_72_20

Rights and Permissions

The common cause of parotid fistula is parotid gland surgery and is frequently due to injury to the gland rather than to the duct. The frequency of postparotidectomy fistula is 14%. Other causes include facial trauma, congenital anomalies of the parotid gland, malignancies originating from the parotid gland and infections. Although there are several options for the treatment of parotid fistula and Frey's syndrome, very few treatment options are deemed optimal. The use of Botulinum A neurotoxin as a conservative method of treatment for parotid fistula and Frey's syndrome is a recent and evolving concept.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded48    
    Comments [Add]    

Recommend this journal